Patents by Inventor Kang Le

Kang Le has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10428057
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: October 1, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael J. Soth, Gang Liu, Kang Le, Jason Cross, Philip Jones
  • Publication number: 20190270736
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 5, 2019
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Patent number: 10344025
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: July 9, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20190144425
    Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 16, 2019
    Inventors: Philip JONES, Michael J. SOTH, Jason P. BURKE, Kang LE, Gang LIU
  • Publication number: 20190092764
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Application
    Filed: September 4, 2018
    Publication date: March 28, 2019
    Inventors: Michael J. SOTH, Gang LIU, Kang LE, Jason CROSS, Philip JONES
  • Patent number: 10150753
    Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 11, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip Jones, Michael J. Soth, Jason P. Burke, Kang Le, Gang Liu
  • Patent number: 10093664
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 9, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael J. Soth, Gang Liu, Kang Le, Jason Cross, Philip Jones
  • Patent number: 10053431
    Abstract: Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 21, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Shaoqing Chen, Andrew F. Donnell, Robert Francis Kester, Kang Le, Yan Lou, Christophe Michoud, Stacy Remiszewski, Kenneth C. Rupert, Martin Weisel
  • Publication number: 20180186781
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Application
    Filed: December 8, 2017
    Publication date: July 5, 2018
    Inventors: Michael J. SOTH, Gang LIU, Kang LE, Jason CROSS, Philip JONES
  • Publication number: 20180057507
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Application
    Filed: August 28, 2017
    Publication date: March 1, 2018
    Inventors: Michael J. SOTH, Philip JONES, James RAY, Gang LIU, Kang LE, Jason CROSS
  • Patent number: 9809588
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 7, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20170291895
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 12, 2017
    Inventors: Maria Emilia DI FRANCESCO, Philip JONES, Timothy HEFFERNAN, Matthew M. HAMILTON, Zhijun KANG, Michael J. SOTH, Jason P. BURKE, Kang LE, Christopher Lawrence CARROLL, Wylie S. PALMER, Richard LEWIS, Timothy MCAFOOS, Barbara CZAKO, Gang LIU, Jay THEROFF, Zachary HERRERA, Anne YAU
  • Publication number: 20170174661
    Abstract: Disclosed herein is the compound (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl)acetamido)pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide, and salt forms and polymorphs thereof demonstrating improved exposure after oral dosing. Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 22, 2017
    Inventors: Philip JONES, Michael J. SOTH, Jason B. BURKE, Kang LE, Gang LIU
  • Publication number: 20160272596
    Abstract: Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 22, 2016
    Inventors: Shaoqing Chen, Andrew F. Donnell, Robert Francis Kester, Kang Le, Yan Lou, Christophe Michoud, Stacy Remiszewski, Kenneth C. Rupert, Martin Weisel
  • Patent number: 9422332
    Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, m, n and q are described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: August 23, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joan Heather Hogg, Kang Le, Yan Lou, Steven Gregory Mischke, Stacy Remiszewski
  • Patent number: 9394263
    Abstract: There are provided compounds of the formula wherein: V, W, X, Y, Z, R1, R2, R3, R4, R5 and R6 are described herein. The compounds are useful for the treatment of proliferative diseases, including cancer.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: July 19, 2016
    Assignee: F. HOFFMANN-LA ROCHE AG
    Inventors: Andrew F. Donnell, Xiaochun Han, Robert Francis Kester, Norman Kong, Kang Le, Yan Lou, Christophe Michoud, John Anthony Moliterni, Stacy Remiszewski, Kenneth Carey Rupert, Weiya Yun
  • Publication number: 20160009704
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 14, 2016
    Applicant: Board of Regents, The University of Texas System
    Inventors: Maria Emilia Di Francesco, Philip Jones, Timothy Heffernan, Matthew M. Hamilton, Zhijun Kang, Michael J. Soth, Jason P. Burke, Kang Le, Christopher Lawrence Carroll, Wylie S. Palmer, Richard Lewis, Timothy McAfoos, Barbara Czako, Gang Liu, Jay Theroff, Zachary Herrera, Anne Yau
  • Publication number: 20160002248
    Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria Emilia Di Francesco, Timothy Heffernan, Michael J. Soth, Kang Le, Christopher Lawrence Carroll, Timothy McAfoos, Jason P. Burke, Jay Theroff, Zhijun Kang, Philip Jones
  • Publication number: 20150361059
    Abstract: There are provided compounds of the formula wherein: V, W, X, Y, Z, R1, R2, R3, R4, R5 and R6 are described herein. The compounds are useful for the treatment of proliferative diseases, including cancer.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 17, 2015
    Applicant: Hoffman-La Roche Inc.
    Inventors: Andrew F. Donnell, Xiaochun Han, Robert Francis Kester, Norman Kong, Kang Le, Yan Lou, Christophe Michoud, John Anthony Moliterni, Stacy Remiszewski, Kenneth Carey Rupert, Weiya Yun
  • Publication number: 20150210739
    Abstract: Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, m, n and q are described in this application, and methods of using said compounds in the treatment of cancer.
    Type: Application
    Filed: August 6, 2013
    Publication date: July 30, 2015
    Inventors: Joan Heather Hogg, Kang Le, Yan Lou, Steven Gregory Mischke, Stacy Remiszewski